SureTrader
Home > Boards > Canadian > Biotechs >

Trillium Therapeutics Inc. (TRIL)

TRIL RSS Feed
Add TRIL Price Alert      Hide Sticky   Hide Intro
Moderator: NY1972
Search This Board:
Last Post: 8/25/2016 11:37:16 PM - Followers: 33 - Board type: Free - Posts Today: 0

Trillium Therapeutics Inc. (NASDAQ:TRIL, TSX:TR)

Home: http://trilliumtherapeutics.com/trillium-home/default.aspx

 

Trillium Therapeutics Inc. 
2488 Dunwin Drive 
Mississauga, Ontario, 
Canada L5L 1J9 
Tel: +1 416.595.0627

 

Trillium Therapeutics is an immuno-oncology company dedicated to the discovery and development of novel and innovative cancer therapies. We have two premier pre-clinical programs, SIRPαFc and a CD200 monoclonal antibody, which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. 

 

SEC filings:  http://www.nasdaq.com/symbol/tril/sec-filings

 

Twitter:  https://twitter.com/search?q=%24TRIL&src=ctag

 

Quote:  https://www.google.com/finance?q=NASDAQ%3ATRIL&ei=dWJkV-kHiKV5wPiX4As

 

Canadian Insider:  https://www.canadianinsider.com/company?menu_tickersearch=tr

 
Currency Converter: http://www.bankofcanada.ca/en/rates/converter.html


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Last update 6/17/2016

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TRIL
Current Price
Volume:
Bid Ask Day's Range
SureTrader
TRIL News: Report of Foreign Issuer (6-k) 08/23/2016 07:02:06 AM
TRIL News: Report of Foreign Issuer (6-k) 08/17/2016 07:09:10 AM
TRIL News: Report of Foreign Issuer (6-k) 08/12/2016 07:14:55 AM
TRIL News: Report of Foreign Issuer (6-k) 06/07/2016 07:21:19 AM
TRIL News: Report of Foreign Issuer (6-k) 05/31/2016 07:36:22 AM
PostSubject
#330   "there are other immune targets. Many immune therapies NY1972 08/25/16 11:37:16 PM
#329   TTI621 binds to cancer cells mostly, RBC poorly. NY1972 08/25/16 12:56:09 PM
#328   It all sounds pretty amazing. DFRAI 08/25/16 09:23:49 AM
#327   TAM is a major stromal, metastasis component. Slowing NY1972 08/24/16 10:38:28 AM
#326   I was thinking more along the lines of jondoeuk 08/23/16 11:34:12 PM
#325   TRIL is taking serial, on-treatment tumor biopsies of NY1972 08/23/16 07:00:27 PM
#324   Thanks for this. I wonder why they are jondoeuk 08/23/16 03:37:01 PM
#323   Time to present some in vivo solid tumor data. NY1972 08/23/16 11:31:20 AM
#322   TTI-621 P1 Exclusion Criteria: NY1972 08/22/16 08:46:00 PM
#321   1 MDVN > 100 TRIL NY1972 08/22/16 12:05:45 PM
#320   Fighting cancer like an infection NY1972 08/21/16 12:16:13 PM
#319   From detailed evaluation of serial, on-treatment tumor biopsies NY1972 08/18/16 08:52:40 PM
#318   Skoal tobacco packed in his lip => cancer NY1972 08/18/16 06:03:10 PM
#317   Review Time for initial submission of an Investigational NY1972 08/18/16 12:38:50 PM
#316   Intratumoral injection of SD-101 + ipilimumab + radiation NY1972 08/18/16 10:22:41 AM
#315   Does anyone know when the company put in jondoeuk 08/18/16 10:06:16 AM
#314   Tioma expects to advance its lead candidate to NY1972 08/17/16 10:57:52 PM
#313   Boom Shaka_Zulu 08/17/16 10:54:52 AM
#312   Mycosis Fungoides is the most common form of NY1972 08/17/16 09:42:07 AM
#311   TRILLIUM THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH LongRun8 08/17/16 07:19:30 AM
#310   SP @ $11, EV = 50 mil. for NY1972 08/16/16 12:23:51 PM
#309   Tioma Therapeutics, Inc., a venture-stage biopharmaceutical company developing NY1972 08/16/16 09:44:35 AM
#308   On watch Shaka_Zulu 08/16/16 12:18:45 AM
#307   TTi-622 for MS? NY1972 08/15/16 08:52:01 PM
#306   From dewophile: NY1972 08/12/16 07:39:41 PM
#305   CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small DFRAI 08/12/16 03:00:51 PM
#304   Notes As of June 30, 2016, Trillium had cash NY1972 08/12/16 12:45:25 PM
#303   6K NY1972 08/12/16 09:49:52 AM
#302   CD47> Stanford mouse study using anti-CD47 (no chemo) biocqr 08/12/16 09:19:45 AM
#301   Trillium 3rd best stock in biotech based on analysis pphm_mike 08/12/16 04:12:11 AM
#300   NYTimes opinion article NY1972 08/09/16 09:33:50 PM
#299   Better than Nivolumab?? NY1972 08/08/16 09:50:34 AM
#298   Anti-CD47 Agents NY1972 08/06/16 08:49:47 PM
#297   Patient selection NY1972 08/06/16 12:14:00 AM
#296   Key IO combos NY1972 08/05/16 12:54:25 PM
#295   WW IO market NY1972 08/05/16 12:40:50 PM
#294   Cell division control protein 42 (Cdc42) has been NY1972 08/05/16 11:43:55 AM
#293   Value of a IO drug for treating patients NY1972 08/05/16 09:53:46 AM
#292   Competitors: NY1972 08/04/16 10:08:27 PM
#291   CSC NY1972 08/04/16 09:14:39 AM
#290   More than half of all BRD4 proteins are NY1972 08/03/16 01:39:12 PM
#289   Price targets: NY1972 08/03/16 10:07:35 AM
#288   Antibodies could combat atherosclerosis as well as tumor biocqr 08/02/16 02:31:10 PM
#287   The chart says 'Don't eat me', Stanford research NY1972 08/01/16 02:34:09 PM
#286   Antibody Therapy Targeting CD47 and CD271 biocqr 08/01/16 11:55:25 AM
#285   10 centers recruiting subjects with relapsed or refractory NY1972 07/31/16 11:26:52 AM
#284   Harnessing the Immune System to Fight Cancer NY1972 07/30/16 01:31:17 PM
#283   News related to Hu5F9-G4: NY1972 07/28/16 04:43:16 PM
#282   long overdue for news super_trades 07/28/16 11:55:46 AM
#281   5746 traded, no expectation or dilution before ASH. NY1972 07/26/16 10:22:39 PM
PostSubject